Stocks Health care MSLE
NASDAQ · Health careSatellos Bioscience Inc. (MSLE)
It posted a net loss of $24.9M. In fiscal 2025 capital spending exceeded operating cash flow by $23.6M. At December 31, 2025 it held $9.8M in cash. Its latest periodic report to the SEC is the annual report (Canadian issuer) (40-F) filed on March 27, 2026.
What Satellos Bioscience Inc. does
Satellos Bioscience Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker MSLE.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$24.9M | -$1.70 | -$23.6M |
| 2025 | n/a | -$20.6M | -$2.16 | -$18.3M |
Latest SEC filings
What Satellos Bioscience Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 24, 2026
- September 15, 2026
- September 9, 2026
- September 1, 2026
- August 14, 2026
- August 14, 2026Form SUPPL filing SUPPL
- August 13, 2026
- August 11, 2026Form F-X filing F-X
- August 11, 2026Form F-10 filing F-10
- July 8, 2026
Questions about MSLE
What does Satellos Bioscience Inc. do?
Satellos Bioscience Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker MSLE.
Is Satellos Bioscience Inc. profitable?
No. In fiscal 2025 it reported a net loss of $24.9M.
When did Satellos Bioscience Inc. last report?
Its most recent periodic report is the annual report (Canadian issuer) (40-F) filed on March 27, 2026. It covers the period to December 31, 2025. Its newest filing of any kind is the foreign issuer update from September 24, 2026.
Similar companies
Follow MSLE
Get an email when Satellos Bioscience Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow MSLE: get an email when it filesWhere the numbers come from
Financial figures are the values Satellos Bioscience Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.